The global antiulcerant drugs market growth outlook is positive with significant growth potential for antiulcerant drugs market in emerging countries. Rising disposable income in developed countries, growing awareness of the disease, busy lifestyles, technological advances such as big data, 3D printing and IoT is aiding the antiulcerant drugs market growth.
The market for antiulcerant drugs is fragmented with a large number of players. Major players in the market are AstraZeneca PLC, Allergan plc, Daewoong Pharmaceutical Co., Ltd., Eisai Co., Ltd., Takeda Pharmaceutical Company others. Proton Pump Inhibitors accounted for the largest share of the market for antiulcerant drugs market in 2017. The highest growth is projected to come from H2 Receptor Antagonists segment. Major factors included an aging population, sedentary lifestyles and increasing awareness on ulcer disease.
North America is the largest market for antiulcerant drugs market. It was followed by Asia Pacific and Western Europe. Going forward, Africa is expected to witness the fastest growth in the antiulcerant drugs market, followed by North America.
The USA is the largest market in terms of value and in the antiulcerant drugs market. India and China are forecasted to have the fastest growth. The market is challenged by restraints such as unfavorable laws for drug patents and rising trade protectionism.
- Allergan Plc.
- Astrazeneca Plc
- Daewoong Pharmaceutical Co., Ltd.
- Eisai Co., Ltd.
- Takeda Pharmaceutical Company Limited
For more information about this report visit https://www.researchandmarkets.com/research/dx47qb/antiulcerant?w=4
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.